Centessa Pharmaceuticals Announces Dosing Of First Subject In Registrational PRESent-3 Study Evaluating SerpinPC For The Treatment Of Hemophilia B With Inhibitors
Portfolio Pulse from Benzinga Newsdesk
Centessa Pharmaceuticals has announced the dosing of the first subject in its PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors. The dosing phase follows a 12-week observation period during which baseline data of the subject's disease status under their current therapy are collected. The company began dosing subjects in the PRESent-2 study for the treatment of hemophilia B without inhibitors in July 2023. The FDA has granted Fast Track designation to SerpinPC for the treatment of hemophilia B, with or without inhibitors.
October 31, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Centessa Pharmaceuticals has begun dosing in its PRESent-3 study of SerpinPC, a potential treatment for hemophilia B. The FDA has granted Fast Track designation to SerpinPC.
The news is directly related to Centessa Pharmaceuticals and its product SerpinPC. The initiation of the dosing phase in the PRESent-3 study and the Fast Track designation by the FDA are positive developments that could potentially accelerate the drug's approval process and market entry, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100